Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02884089 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02884089 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 40 participants.
The verdict
NCT02884089, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented. Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights. The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Abemaciclib
- DRUG Iohexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02884089
The ClinicalTrials.gov registry entry for NCT02884089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02884089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02884089 about?
NCT02884089 is a clinical study titled "A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants". This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will al...
What is the current status of trial NCT02884089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02884089?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Abemaciclib (DRUG), Iohexol (DRUG).
Who is sponsoring clinical trial NCT02884089?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.